Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma

Tumor Biology

Volumn 36, Issue 8, 2015, Pages 6559-6568

  Che, Juanjuan ^a   Yang, Yifan ^a   Xiao, Jing ^a   Zhao, Pengfei ^a   Yan, Bo ^b   Dong, Shuo ^c   Cao, Bangwei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b University of Texas Health Science Center   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Claudin 3; Epithelial mesenchymal transition; Prognosis; Squamous cell lung carcinoma

Indexed keywords

BETA CATENIN; CLAUDIN 3; UVOMORULIN; VIMENTIN; CADHERIN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; WESTERN BLOTTING; AGED; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; BETA CATENIN; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CLAUDIN-3; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84940435178     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3350-1     Document Type: Article

References (41)

1. Soini Y. Tight junctions in lung cancer and lung metastasis. A review. Int J Clin Exp Pathol. 2012;5:126–36. PubMed: 22400072.
2. Moore W, Talati R, Bhattacharji P, Bilfinger T. Five-year survival after cryoablation of stage I non-small cell lung cancer in medically inoperable patients. J Vasc Interv Radiol. 2015;26:312–9. PubMed: 25735518.
3. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67:257–74. PubMed: 19914732.
4. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non–small cell lung cancers. Clin Cancer Res. 2005;11:1167–73. PubMed: 15709185.
5. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–44. PubMed: 16014883.
6. Nichols LS, Ashfaq R, Iacobuzio-Donahue CA. Claudin 4 protein expression in primary and metastatic pancreatic cancer support for use as a therapeutic target. Am J Clin Pathol. 2004;121:226–30. PubMed: 14983936.
7. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol. 2005;18:511–8. PubMed: 15475928.
8. Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, et al. Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci. 2011;102:2248–54. PubMed: 21883696.
9. Shang X, Lin X, Alvarez E, Manorek G, Howell SB. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia. 2012;14:974–85. PubMed: 23097631.
10. Chao YC, Pan SH, Yang SC, Yu SL, Che TF, Lin CW, et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med. 2009;179:123–33. PubMed: 18787218.
11. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, et al. Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res. 2004;10:4427–36. PubMed: 15240533.
12. Merikallio H, Kaarteenaho R, Pääkkö P, Lehtonen S, Hirvikoski P, Mäkitaro R, et al. Impact of smoking on the expression of claudins in lung carcinoma. Eur J Cancer. 2011;47:620–30. PubMed: 21106366.
13. Moldvay J, Jäckel M, Páska C, Soltész I, Schaff Z, Kiss A. Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer. 2007;57:159–67. PubMed: 17418912.
14. Gao F, Duan X, Lu X, Liu Y, Zheng L, Ding Z, et al. Novel binding between pre-membrane protein and claudin-1 is required for efficient dengue virus entry. Biochem Biophys Res Commun. 2010;391:952–7. PubMed: 19962368.
15. Van Itallie CM, Betts L, Smedley JG, McClane BA, Anderson JM. Structure of the claudin-binding domain of Clostridium perfringens enterotoxin. J Biol Chem. 2008;283:268–74. PubMed: 17977833.
16. Saeki R, Kondoh M, Kakutani H, Matsuhisa K, Takahashi A, Suzuki H, et al. A claudin-targeting molecule as an inhibitor of tumor metastasis. J Pharmacol Exp Ther. 2010;334:576–82. PubMed: 20442222.
17. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010;29:2047–59. PubMed: 20101235.
18. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101:293–9. PubMed: 19961486.
19. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96. PubMed: 11156236.
20. Choi YS, Shim YM, Kim S-H, Son DS, Lee H-S, Kim GY, et al. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2003;24:441–9. PubMed: 12965318.
21. Chiu CG, Chan SK, Fang ZA, Masoudi H, Wood-Baker R, Jones SJ, et al. Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. Am J Surg. 2012;203:654–9. PubMed: 22402266.
22. Richardson F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, et al. The evaluation of E-cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy. Anticancer Res. 2012;32:537–52. PubMed: 22287743.
23. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66. PubMed: 19153669.
24. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, et al. Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008;130:481–94. PubMed: 18648847.
25. Merikallio H, Kaarteenaho R, Pääkkö P, Lehtonen S, Hirvikoski P, Mäkitaro R, et al. Zeb1 and twist are more commonly expressed in metastatic than primary lung tumours and show inverse associations with claudins. J Clin Pathol. 2011;64:136–40. PubMed: 21131312.
26. Lee KW, Lee NK, Kim JH, Kang MS, Yoo HY, Kim HH, et al. Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer. Biochem Biophys Res Commun. 2012;423:454–60. PubMed: 22668877.
27. Jung JH, Jung CK, Choi HJ. Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas. Pathol Res Pract. 2009;205:409–16. PubMed: 19231096.
28. Romanov V, Whyard TC, Waltzer WC, Gabig TG. A claudin 3 and claudin 4-targeted Clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells. Cancer Lett. 2014;351:260–4. PubMed: 24952257.
29. Yao Q, Zheng QM, Wen JF, Lü T, Wei MQ, Dai SZ. Target-specific cytotoxic activity of recombinant fusion toxin C-CPE-ETA’ against CLDN-3,4-overexpressing ovarian cancer cells. Zhonghua Zhong Liu Za Zhi. 2010;32:897–902. PubMed: 21223796.
30. Ersoz S, Mungan S, Cobanoglu U, Turgutalp H, Ozoran Y. Prognostic importance of claudin-1 and claudin-4 expression in colon carcinomas. Pathol Res Pract. 2011;207:285–9. PubMed: 21493012.
31. Merikallio H, Pääkkö P, Harju T, Soini Y. Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers. Int J Clin Exp Pathol. 2011;4:667–73. PubMed: 22076167.
32. Prudkin L, Liu DD, Ozburn NC, Sun M, Behrens C, Tang X, et al. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol. 2009;22:668–78. PubMed: 19270647.
33. Hirata T, Fukuse T, Naiki H, Wada H. Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin Lung Cancer. 2001;3:134–40. PubMed: 14659029.
34. Hommura F, Furuuchi K, Yamazaki K, Ogura S, Kinoshita I, Shimizu M, et al. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer. 2002;94:752–8. PubMed: 11857309.
35. Zhang Y, Han Y, Zheng R, Yu J-H, Miao Y, Wang L, et al. Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC. Tumour Biol. 2012;33:1437–44. PubMed: 22528942.
36. Pirinen RT, Hirvikoski P, Johansson RT, Hollmén S, Kosma VM. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol. 2001;54:391–5. PubMed: 11328840.
37. Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H, et al. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 2013;66:937–45. PubMed: 23853314.
38. Kim SH, Kim JM, Shin M, Kim CW, Huang SM, Kang DW, et al. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung. Histol Histopathol. 2012;27:581–91. PubMed: 22419022.
39. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28. PubMed: 17508028.
40. Angelow S, Ahlstrom R, Yu AS. Biology of claudins. Am J Physiol Renal Physiol. 2008;295:F867–76. PubMed: 18480174.
41. Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P, et al. Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer. 2011;11:73. PubMed: 21324165.